Announcement on Voluntary Disclosure of Acceptance of the Marketing Application for iza-bren (EGFR×HER3 dual-antibody ADC) for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Acceptance of the Marketing Application for iza-bren (EGFR×HER3 dual-antibody ADC) for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A